Non-steroidal compounds useful as glucocorticoid receptor modulators
View Patent ↗This invention relates to novel amino acid derivatives of formula (I) wherein the R groups have the following meanings: —R 1 is —H or —(1-4C)alkyl; —R 2 is —C(O)R 15 or —S(O) 2 R 15 ; —R 3 is —H, —(1-4C)alkyl or —OR 16 ; —R 4 is —H, —(1-4C)alkyl or —OR 16 ; —R 6 is —H or —C(R 16 )NOR 16 ; —R 7 is —H, -halogen, -cyano; —(1-6C)alkyl, —(2-6C)alkenyl or —(2-6C)alkynyl, all optionally substituted with -amino, -hydroxyl or -halogen; —R 8 is —H, -cyano, -halogen, -nitro; —(1-6C)alkyl, —(2-6C)alkenyl, —(2-6C)alkynyl or —O(1-6C)alkyl, all optionally substituted with -amino, -hydroxyl or -halogen; -(hetero)aryl, optionally substituted with -cyano, -halogen, —(1-4C)alkyl, —(1-4C)alkoxy, —(1-4C)alkoxy(1-4C)alkyl or -(hetero)aryl; —C(R 16 )NOR 16 ; —C(O)N(R 17 ) 2 ; —C(O)R18, —C(O)OR 19 , —NHC(O)R 20 , or —NHS(O) 2 R 21 ; —R 9 is —H, -halogen, -cyano, or —(1-4C)alkyl, optionally substituted with -halogen; —R 10 is —H or —(1-4C)alkyl; —R 11 is —H; —R 12 is —H, -cyano or —(1-4C)alkyl; —R 13 is —H, —(1-4C)alkyl, -halogen or -formyl; —R 14 is —H, -halogen, -cyano, —(1-4C)alkyl or -(hetero)aryl; or a pharmaceutically acceptable salt thereof. The compounds of this invention are highly specific for the glucocorticoid receptor and may be used for treating inflammatory diseases.
1. A compound according to Formula I:
or a pharmaceutically acceptable salt thereof,
wherein the R groups have the following meanings:
—R 1 is —H or —(1-4C)alkyl;
—R 2 is —C(O)R 15 or —SO 2 R 15 ;
—R 3 is —H, —(1-4C) alkyl or —OR 16 ;
—R 4 is —H, —(1-4C)alkyl or —OR 16 ;
—R 6 is —H or —C(R 16 )NOR 16 ;
—R 7 is —H, -halogen, -cyano;
—(1-6C) alkyl, —(2-6C)alkenyl or —(2-6C)alkynyl, all optionally substituted with amino, -hydroxyl or -halogen;
—R 8 is —H, -cyano, -halogen, -nitro;
—(1-6C) alkyl, —(2-6C)alkenyl, —(2-6C)alkynyl or —O(1-6C)alkyl, all optionally substituted with -amino, -hydroxyl or -halogen;
-(hetero)aryl, optionally substituted with -cyano, -halogen, —(1-4C)alkyl, —(1-4C)alkoxy, —(1-4C)alkoxy(1-4C)alkyl or -(hetero)aryl;
—C(R 16 )NOR 16 , —C(O)N(R 17 ) 2 , —C(O)R 18 , —C(O)OR 19 , —NHC(O)R 20 , or —NHS(O) 2 R 21 ;
—R 9 is —H, -halogen, -cyano, or —(1-4C)alkyl, optionally substituted with -halogen;
—R 10 is —(1-4C)alkyl;
—R 11 is —H;
—R 12 is —H, -cyano or —(1-4C)alkyl;
—R 13 is —H, —(1-4C)alkyl, -halogen or -formyl;
R 14 is —H, -halogen, -cyano, —(1-4C)alkyl or -(hetero)aryl;
—R 15 is —H;
—(1-6C)alkyl, —(2-6C)alkenyl, —(2-6C)alkynyl, —O(2-6C)alkyl, -O(2-6C)alkenyl or —O(2-6C)alkynyl, all optionally substituted with one or more —OH, -halogen, -cyano or -(hetero)aryl;
-(hetero)aryl, optionally substituted with —(1-4C)alkyl, -halogen or —NH 2 ;
—NH 2 , —(di)(1-4C)alkylamino, —(1-4C)alkylthio(1-4C)alkyl, —(1-4C)alkoxy(1-4C)alkyl or —NR 16 OR 16 ;
—R 16 is —H, —(1-6C)alkyl, —(2-6C)alkenyl or —(2-6C)alkynyl;
—R 17 is —H;
—(1-6C)alkyl, optionally substituted with -halogen, —(1-4C)alkoxy or -(hetero)aryl, optionally substituted with -halogen, —(1-4C)alkyl or —(1-4C)alkoxy;
—(3-6C)cycloalkyl or -(hetero)aryl, optionally substituted with -halogen, —(1-4C)alkyl or —(1-4C)alkoxy;
—R 18 is —H, —NH 2 or —(1-4C)alkyl, optionally substituted with —OH, -halogen, -cyano or —S(1-4C)alkyl;
—R 19 is —H or —(1-6C)alkyl, optionally substituted with —OH or -halogen; and
—R 20 is —H;
—(1-6C)alkyl or —(2-6C)alkenyl, both optionally substituted by -halogen, —O(1-6C)alkyl, -(hetero)aryl, optionally substituted with —(1-4C)alkyl or halogen;
—(3-6C)cycloalkyl, —(1-6C)alkoxy; or
-(hetero)aryl, optionally substituted with —(1-4C)alkyl); —NH 2 , —NH(1-6C)alkyl or —NH(hetero)aryl);
—R 21 is —H or —(1-6C)alkyl.
2. A compound according to claim 1 wherein —R 3 , —R 6 , —R 7 , —R 9 , —R 12 , —R 13 , —R 14 and —R 16 are —H and —R 4 are —H or —(1-4C)alkyl.
3. A compound according to claim 1 , wherein
—R 1 is —H;
—R 8 is —H, -cyano or -halogen;
-(hetero)aryl, optionally substituted with —(1-4C)alkyl;
—C(R 16 )NOR 16 , —C(O)N(R 17 ) 2 , —C(O)R 18 or —C(O)OR 19 ;
—R 10 is —(1-4C)alkyl;
—R 15 is —(1-6C)alkyl, optionally substituted with one or more -halogen or -(hetero)aryl;
-(hetero)aryl, optionally substituted with —(1-4C)alkyl or —NH 2 ; or —(di)(1 -4C)alkylamino;
—R 17 is -(hetero)aryl, optionally substituted with —(1-4C)alkoxy;
—R 18 is —(1-4C)alkyl and
—R 19 is —(1-6C)alkyl.
4. A compound selected from the group of
rel-N-[(2R,10R,14bR)-8-bromo-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,2,2-trifluoroacetamide;
rel-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,2,2-trifluoroacetamide;
rel-2,2-dichloro-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide
rel-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide;
rel-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,2-difluoroacetamide;
rel-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]methanesulfonamide;
rel-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f pyrido[1,2-a]azepin-2-yl]ethanesulfonamide;
rel-N′-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-N,N-dimethylaminosulfamide;
rel-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-3,5 -dimethylisoxazole-4-carboxamide;
rel-N-[(2R,10R,14bR)-8-acetyl- 1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,2,2-trifluoroacetamide;
rel-N-[(2R,10R,14bR)-8-acetyl- 1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-8-[1-(hydroxyimino)ethyl]-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-2,2-dichloro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-2-chloro-2,2-difluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]isoxazole-5 -carboxamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-5-methyl-isoxazole-3-carboxamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2-thiophenacetamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]methanesulfonamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]ethanesulfonamide;
rel-N′-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-N,N-dimethylaminosulfamide;
rel-2,2-difluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-4-amino-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-1,2,5-oxadiazole-3-carboxamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyrimidin-2-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyrimidin-2-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyrazin-2-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
methyl rel-(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-2-(2,2,2-trifluoroacetylamino)dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxylate;
ethyl rel-(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl 2-(2,2,2-trifluoroacetylamino)dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxylate;
propyl rel-(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl 2-(2,2,2-trifluoroacetylamino)dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxylate;
rel-(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-N-phenyl-2-(2,2,2-trifluoroacetylamino)dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide;
rel-(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-N-(pyridin-4-yl)-2-(2,2,2-trifluoroacetylamino)dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide;
rel-(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-N-(2-methoxypyrimidin-5-yl)-10-methyl-2-(2,2,2-trifluoroacetylamino)dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide;
rel-(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-N-(2-methoxyphenyl)-10-methyl-2-(2,2,2-trifluoroacetylamino)-dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-ethyltetrazol-5-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-2-chloro-2,2-difluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-methyltetrazol-5-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-methyltetrazol-5-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyrimidin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-2-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyrimidin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide;
rel-2,2-chloro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyrimidin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyrimidin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]methanesulfonamide;
rel-2-chloro-2,2-difluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyrimidin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-5-amino-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyrimidin-4-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-1,2,5-oxadiazole-4-carboxamide;
rel-2,2,2-trifluoro-N-[(2R,4S,10R,14bR)-1,2,3,4,10,14b-hexahydro-4,10-dimethyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-N′-methyl-N′-methoxyurea;
rel-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexabydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2-hydroxyacetamide;
rel-(2R,10R,14bR)-2-[(N,N-dimethylaminocarbonyl)amino]-1,2,3,4,10,14b-hexahydro-10-methyl-N-phenyldibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-8-[4,5-dihydrooxazol-2-yl]-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide;
rel-2,2,2-trifluoro-N-[(2R,10R,14bR)-8-formyl-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]acetamide; or
rel-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-8-[1-(hydroxyimino)ethyl]-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide.
5. A pharmaceutical composition which comprises a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
6. A method for treating a disease, condition or disorder responsive to glucocorticoid receptor activity, wherein the disease, condition or disorder is selected from the group consisting of rheumatic disease, dermatological disease, allergic disorder, pulmonary condition and immune and inflammatory disease, the method comprising administering to an individual a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 , wherein the disease is rheumatoid disease.
8. The method of claim 7 , wherein the rheumatoid disease is selected from the group consisting of rheumatoid arthritis, juvenile arthritis and ankylosing spoldylitis.
9. The method of claim 6 , wherein the condition is a pulmonary condition selected from the group consisting of asthma and chronic obstructive pulmonary disease.
10. The method of claim 6 , wherein the dermatological disease is selected from the group consisting of psoriasis and pemphigus.
11. The method of claim 6 , wherein the allergic disorder is selected from the group consisting of allergic rhinitis, atopic dermatitis and contact dermatitis.
12. The method of claim 6 , wherein the immune and inflammatory disease is selected from the group consisting of Crohn disease, ulcerative colitis, systemic lupus erythematosus, autoimmune chronic active hepatitis, osteoarthritis, tendonitis and bursitis.